Skip to content

Web Based Renal Transplant Patient Medication Education

Web Based Renal Transplant Patient Medication Education

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00327483
Enrollment
250
Registered
2006-05-18
Start date
2005-07-31
Completion date
2006-04-30
Last updated
2006-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant Recipients

Keywords

Transplant, Medication error, Patient Safety, Information technology

Brief summary

Information technology will be brought directly to renal transplant recipients to help them learn about the large number of medications they are required to take on a life long basis, in order to prevent errors and improve safety.

Detailed description

Transplant recipients are particularly vulnerable to medication errors because of the large number of chronic drugs needed to prevent rejection and treat comorbidities. Compliance failures directly compromise patient safety through acute immunologic events and premature graft loss. For society, the loss of invested fiscal and organic (organs) resources is catastrophic. As the unique constant in the chain of people who provide, modify and consume prescription medications, health information technology should be focused on empowering the patient to prevent medication errors. Our principal clinical hypothesis is that HIT can be proven to improve patient safety by minimizing medication errors. Specific aims address the creation of new knowledge and evidence ( in a renal transplant population) of benefits of widely applicable HIT tools. Web enabled education of two groups, new (\<6 months) and established (\> 6 months), kidney transplant recipients is proposed.

Interventions

BEHAVIORALInternet based education software

Sponsors

Agency for Healthcare Research and Quality (AHRQ)
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
ECT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

age \> 18 or capable of managing own medications \-

Exclusion criteria

Education level below 10th grade \-

Design outcomes

Primary

MeasureTime frame
Medication errors

Secondary

MeasureTime frame
Serum creatinine
Rejection episodes
Rehospitalizations
Graft loss

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026